Clearmind Medicine Publishes Patent Application for New Ketamine Treatment

Vancouver, Canada, Aug. 29, 2024 - Clearmind Medicine Inc., a clinical-stage biotech company dedicated to the development of psychedelic-derived therapeutics, has announced the publication of its patent application under the international Patent Cooperation Treaty (PCT). This application focuses on innovative combinations of Ketamine and N-Acylethanolamines. The patent filing is a result of the company's ongoing collaboration with SciSparc Ltd., a pharmaceutical company specializing in treatments for central nervous system disorders.

The collaboration between Clearmind and SciSparc aims to create combination therapies that integrate SciSparc's Palmitoylethanolamide (PEA) with Clearmind's novel psychedelic molecule, 5-methoxy-2-aminoindan (MEAI). These therapies are designed to address issues such as addiction, weight loss, and mental health disorders. The partnership is also exploring new treatments based on various psychedelic molecules and PEA. Currently, thirteen patents connected to this collaboration have been filed with the U.S. Patent and Trademark Office, as well as in multiple other countries.

In 2019, the U.S. Food & Drug Administration (FDA) approved a ketamine derivative as a nasal spray for adults. The medication is intended for patients with depression who have not responded to other treatments and those with major depressive disorder (MDD) experiencing suicidal thoughts or behaviors. This treatment has strict usage guidelines: it must be administered in certified medical facilities, be used alongside an antidepressant, and requires a two-hour observation period post-administration to monitor for serious side effects.

Dr. Adi Zuloff-Shani, CEO of Clearmind, emphasized that combining PEA with various compounds could reduce treatment doses while maintaining effectiveness and minimizing side effects. The FDA approved ketamine under strict supervision due to risks of abuse and dependence. Dr. Zuloff-Shani highlighted that the ultimate goal is to provide safe and effective treatments with minimal adverse effects, and the collaboration with SciSparc may lead to such solutions.

Clearmind Medicine Inc. is focused on discovering and developing psychedelic-based therapeutics to address widespread health issues like alcohol use disorder. The company's principal objective is to research psychedelic compounds and aim to commercialize them as regulated medicines, foods, or supplements. Clearmind's intellectual property portfolio includes nineteen patent families and twenty-nine granted patents. The company plans to seek additional patents as necessary to expand its portfolio.

Shares of Clearmind are traded on Nasdaq under the symbol "CMND" and on the Frankfurt Stock Exchange under "CWY0."

SciSparc Ltd. is a clinical-stage pharmaceutical company with a focus on cannabinoid pharmaceuticals. The company is currently developing several drug programs, including SCI-110 for Tourette Syndrome and Alzheimer's disease agitation and SCI-210 for autism and status epilepticus. SciSparc also has a subsidiary involved in the sale of hemp seed oil-based products on Amazon.com.

This partnership between Clearmind and SciSparc represents a significant step forward in the development of new therapeutic options for various health conditions, leveraging the potential benefits of psychedelic and cannabinoid compounds.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!